乳腺癌新型分子靶向药物治疗研究进展

Research progress in targeted drug therapies for breast cancer

乳腺癌是女性最常见的恶性肿瘤之一,尽管一系列较为有效的化疗药物被应用于乳腺癌的治疗,但晚期乳腺癌的疗效仍不乐观。近年来,曲妥珠单抗、拉帕替尼等药物在乳腺癌治疗中获得成功,为乳腺癌的分子靶向治疗开创了一条新的道路。随后出现的帕妥珠单抗,依维莫司、曲妥珠单抗-DM1等均已进入Ⅲ期临床试验,这些新药为进一步提高乳腺癌的疗效,延长乳腺癌患者的生存提供了新的选择。

Breast cancer is the most common cancer in women. Despite a series of more effective chemotherapy drugs are used in the treatment of breast cancer, breast cancer is still not optimistic. In recent years, the success of trastuzumab, lapatinib and other molecular targeted agents in the treatment of breast cancer started a new way for molecular targets in breast cancer therapy. Nowadays, several phase m clinical trails are ongoing for new target agents such as pertuzumab, everolimus and trastuzumab-DM1. These new molecular targeted agents provide a new choice to improve the efficacy and prolong survival time in patients with breast cancer.